| Register | Login | Search | Contact Us | Terms of Use | ||||||
![]() |
|
|
Please install Flash and turn on Javascript. |
|
Tools and Resources
Ephedra/Ma-Huang
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| General Info | |||||||||||||||
|
Active Forms Absorption Dietary Sources |
|||||||||||||||
| Dosage Info | Back to Top | ||||||||||||||
|
|||||||||||||||
| Overview | Back to Top | ||||||||||||||
The safe dosage of ephedra and ephedra-containing products has been heavily debated. The quantity of ephedra alkaloids in dietary supplements, as reported on package labels, is typically around 8 to 25mg per serving, and the usual dosage frequency is two to three times per day and not more than 4 times per day. However, some products may contain larger or smaller amounts of ephedra alkaloids than are listed on the product label. In one study, 11 of 20 supplements tested either failed to list the alkaloid content on the label or had more than a 20 percent difference (either lower or higher) between the amount listed on the label and the actual amount.(7) It is also important to realize that usually the ephedra weight loss products contain other stimulating ingredients, such as caffeine, guarana and bitter orange (citrus aurantium) which contains synephrine. There have not been many clinical studies conducted on this traditionally used herb. A recent review of 140 reports of adverse events related to the use of dietary supplements containing ephedra alkaloids was conducted. These reports were submitted to the FDA between June 1, 1997, and March 31, 1999. Thirty-one percent of cases were considered to be definitely or probably related to the use of supplements containing ephedra alkaloids, and 31 percent were deemed to be possibly related. Among the adverse events that were deemed definitely, probably, or possibly related to the use of supplements containing ephedra alkaloids, 47 percent involved cardiovascular symptoms and 18 percent involved the central nervous system. Hypertension was the single most frequent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); and seizures (7). Ten events resulted in death, and 13 events produced permanent disability, representing 26 percent of the definite, probable, and possible cases. It is worth noting that several of the reports reviewed in the study involved individuals with pre-existing medical condi |
|||||||||||||||
| Toxicities & Precautions | Back to Top | ||||||||||||||
|
General In recommended dosages, ephedra has a long history of being safe. Exceeding the recommended dose will not improve results and may cause serious adverse health effects.(8) Health Conditions Use with extreme caution in individuals with renal impairment, glaucoma, hypertension, cardiovascular disease, thyroid disease, diabetes, psychiatric disorders, seizure disorders, difficulty urinating or enlarged prostate.(9, 10, 11, 12, 13, 14) Side Effects If abused, taken in high dosages, or taken in pre-existing cardiovascular diseases, ephedra may contribute to adverse events. There are several deaths reported from overdosage of ephedra.(15, 16) Symptoms of overdosage include heart palpitations, extreme nervousness, sweating, enlarged pupils, severe headache, dizziness, dyspnea, elevated body temperature, and ultimately death.(17) There has been a report of hepatitis associated with the use of ephedra.(18) |
|||||||||||||||
| Symptoms & Causes of Deficiency | |||||||||||||||
| Footnotes | Back to Top | ||||||||||||||
|
1 PDR for Herbal Medicines, 2nd ed. Montvale, NJ: Medical Economics Company; 2000:489. 2 American Herbal Products Association. Current Trade Recommendations, AHPA Code of Ethics and Business Conduct. Silver Spring, MD: American Herbal Products Association; Mar1994. 3 Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. J Ethnopharmacol. Apr1991;32(1-3):201-8. View Abstract 4 Chan EL, et al. History of medicine and nephrology in Asia. Am J Nephrol. 1994;14(4-6):295-301. View Abstract 5 Adverse Events Associated with Ephedrine-Containing Products--Texas, December 1993-September 1995. Morbidity Mortality Weekly Report MMWR. Aug1996;45(32):689-92. View Abstract 6 Glennon RA, et al. (+)Amphetamine-stimulus generalization to an herbal ephedrine product. Pharmacol Biochem Behav. Apr2000;65(4):655-8. View Abstract 7 Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm. May2000;57(10):963-9. View Abstract 8 Haller CA, Benowitz NL. Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids. N Engl J Med. Dec2000;343(25):1833-8. View Abstract 9 LaValle JB, et al. Natural Therapeutics Pocket Guide. Hudson, OH: LexiComp, Inc; 2000:429-430. 10 Powell T, et al. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. Jul1998;32(1):153-9. View Abstract 11 Zaacks SM, et al. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol. 1999;37(4):485-9. View Abstract 12 Jacobs KM, et al. Psychiatric complications of Ma-huang. Psychosomatics. Jan2000;41(1):58-62. 13 Capwell RR. Ephedrine-induced mania from an herbal diet supplement. Am J Psychiatry. Apr1995;152(4):647. 14 Harada M, et al. Contribution of alkaloid fraction to pressor and hyperglycemic effect of crude Ephedra extract in dogs. J Pharmacobiodyn. Sep1981;4(9):691-9. View Abstract 15 Thoeharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol. Oct1997;17(5):437-9. 16 Gurley BJ, et al. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit. Aug1998;20(4):439-45. View Abstract 17 PDR for Herbal Medicines, 2nd ed. Montvale, NJ: Medical Economics Company; 2000:489. 18 Nadir A, et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol. Jul1996;91(7):1436-8. View Abstract |
|||||||||||||||